Pfizer (PFE) Announces FDA Approval of XELJANZ for the Treatment of Active Ankylosing Spondylitis
Go back to Pfizer (PFE) Announces FDA Approval of XELJANZ for the Treatment of Active Ankylosing Spondylitis| Pfizer Inc. (NYSE: PFE) | Delayed: 24.72 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $24.72 | 52 Week High | $37.39 | |||
| Open | $24.72 | 52 Week Low | $28.25 | |||
| Day High | $24.72 | P/E | 14.98 | |||
| Day Low | $24.72 | EPS | $1.65 | |||
| Volume | 52,274 | |||||
